H. Witt‐Sullivan

Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies

P. Marotta, K. Peltekian, E. Rampakakis, 2016, European Journal of Clinical Microbiology & Infectious Diseases.

Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy.

M. Sherman, P. Marotta, K. Peltekian, 2009, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

The use of budesonide in the treatment of autoimmune hepatitis in Canada.

Victor K. F. Wong, G. Minuk, E. Yoshida, 2008, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Long term follow-up of patients with chronic hepatitis C treated with interferon alpha.

G. Minuk, J. Heathcote, M. Krajden, 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites?

L. Blendis, K. Sniderman, S. Tobe, 1992, Journal of hepatology.

The canadian multicenter double‐blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis

U. Steinbrecher, G. Minuk, L. Blendis, 1994, Hepatology.

Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies

P. Marotta, K. Peltekian, E. Rampakakis, 2016, European Journal of Clinical Microbiology & Infectious Diseases.

Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada).

M. Sherman, R. Balshaw, R. Myers, 2011, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

The demography of primary biliary cirrhosis in ontario, canada

J. Rankin, L. Blendis, I. Wanless, 1990, Hepatology.

Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa‐2a plus ribavirin

M. Sherman, R. Balshaw, K. Peltekian, 2008, Alimentary pharmacology & therapeutics.